NSCLC Meta-analysis Collaborative Group. Preoperative che-motherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data[J]. Lancet, 2014, 383(9928): 1561-1571. [2]Burdett S, Pignon J P, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2015, 3: CD011430. [3]Nakanishi T, Ross D D. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression[J]. Chin J Cancer, 2012, 31(2): 73-99. [4]Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer[J]. Clin Cancer Res, 2004, 10(5): 1691-1697. [5]王净, 王慧, 袁媛, 等. 全人源抗乳腺癌噬菌体单链抗体库的构建[J]. 现代肿瘤医学, 2011, 19(11): 2139-2142. [6]He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review)[J]. Oncol Lett, 2014, 7(5): 1352-1362. [7]Xie Z Y, Lv K, Xiong Y, et al. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer[J]. Oncol Res Treat, 2014, 37(11): 666-668, 670-672. [8]Dai C L, Liang Y J, Wang Y S, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2[J]. Cancer Lett, 2009, 279(1): 74-83. [9]Filipits M, Haddad V, Schmid K, et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program[J]. Clin Cancer Res, 2007, 13(13): 3892-3898. [10]Nelson A L, Dhimolea E, Reichert J M. Development trends for human monoclonal antibody therapeutics[J]. Nat Rev. Drug Discov, 2010, 9(10): 767-774. [11]Farajnia S, Ahmadzadeh V, Tanomand A, et al. Development trends for generation of single-chain antibody fragments[J]. Immunopharmacol Immunotoxicol, 2014, 36(5): 297-308. [12]罗弋, 庞华, 李淑杰, 等. 人源抗Peroxiredoxin I 肺腺癌噬菌体抗体的制备及鉴定[J]. 南方医科大学学报, 2010, 30(1): 30-34. [13]Luo Y, Pang H, Li S, et al. Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I[J]. Cancer Biol Ther, 2009, 8(14): 1369-1377.
[2]
刘翩,王斌,吴国明.吉非替尼维持治疗晚期肺腺癌长期生存1例[J].第三军医大学学报,2012,34(15):1491. [2]刘瑞青,申淑景,马杰,等.肺腺癌组织中TTF-1和SPA的表达对EGFR突变的临床预测价值[J].第三军医大学学报,2012,34(22):2314. Liu Ruiqing,Shen Shujing,Ma Jie,et al.Clinical value of TTF-1 and SPA expression in predicting EGFR mutations in lung adenocarcinoma[J].J Third Mil Med Univ,2012,34(23):2314. [3]刘小军,张雪琳,李莎莎,等.172例肺腺癌脑转移影响因素的临床分析[J].第三军医大学学报,2013,35(01):73. Liu Xiaojun,Zhang Xuelin,Li Shasha,et al.Clinical analysis of influencing factors for 172 lung adenocarcinoma patients with brain metastasis[J].J Third Mil Med Univ,2013,35(23):73. [4]余祖滨,白莉,姚珂,等.SOCS3对肺腺癌细胞株A549迁移和侵袭能力的影响[J].第三军医大学学报,2008,30(07):588. YU Zu-bin,BAI Li,YAO Ke,et al.Effects of SOCS3 gene on migration and invasion of lung adenocarcinoma cell line A549[J].J Third Mil Med Univ,2008,30(23):588. [5]朱冰,杨建茹,付新平,等.GALV致融性糖蛋白转导肺腺癌细胞的抗肿瘤实验研究[J].第三军医大学学报,2007,29(18):1737. ZHU Bing,YANG Jian-ru,FU Xin-ping,et al.Antitumor effect of GALV membrane fusion glycoprotein on lung adenocarcinoma in vivo and in vitro[J].J Third Mil Med Univ,2007,29(23):1737. [6]庞华,罗弋,李少林.人源肺腺癌噬菌体抗体库的构建及初步筛选[J].第三军医大学学报,2008,30(22):2082. PANG Hua,LUO Yi,LI Shao-lin.Construction of and screening for phage antibody library of human lung adenocarcinoma[J].J Third Mil Med Univ,2008,30(23):2082. [7]白莉,祝蓉,陈智鸿,等.靶向EGFR基因的siRNA表达载体构建及其生物学效应的研究[J].第三军医大学学报,2005,27(23):2307. [8]熊玮,钱桂生,黄桂君.氯氨顺铂诱导耐药后肺腺癌细胞株生物学特性及染色体核型分析[J].第三军医大学学报,2005,27(22):2226. [9]郭芮伶,吴国明,戢福云,等.多西紫杉醇对肺腺癌多药耐药细胞A549/CDDP及其亲代细胞作用机制的初步研究[J].第三军医大学学报,2005,27(07):610. [10]张雪淋,原薇薇,傅华,等.HOXA10在肺腺癌中的过表达及其临床意义[J].第三军医大学学报,2013,35(05):468. Zhang Xuelin,Yuan Weiwei,Fu Hua,et al.Over-expression and clinical significance of HOXA10 in human lung adenocarcinoma[J].J Third Mil Med Univ,2013,35(23):468.
